Marizyme

Marizyme's mission is to improve long-term patient outcomes in cardiac surgery by preserving the structural and functional integrity of vascular grafts during the critical intraoperative period. Its primary achievement is the FDA clearance and commercialization of DuraGraft®, the first and only solution specifically cleared for flushing and storing saphenous vein grafts in CABG, supported by clinical data demonstrating reduced graft wall thickening. The company's strategy is centered on penetrating the global CABG market with DuraGraft while exploring potential platform extensions into other vascular storage applications. Marizyme operates as a public company, focusing its resources on driving surgeon adoption and securing reimbursement pathways for its novel technology.

Proprietary electrolyte solution platform (DuraGraft®) designed to protect vascular grafts from ischemia-reperfusion injury and oxidative stress during intraoperative storage, acting as an antioxidant and cytoprotective agent.

Marizyme faces no direct FDA-cleared competitors, but its primary competition is the entrenched, zero-cost standard of care: heparinized saline. Indirect competition includes systemic pharmacological therapies and alternative revascularization procedures (PCI), but DuraGraft's unique value proposition is its targeted, intraoperative endothelial protection.